In 13 human cancer cell line-derived xenografts, tumors with PTEN loss or PIK3CA mutations are sensitive to PX-866, whereas those harboring RAS-activating mutation show resistance, suggesting that RAS mutation may be an important prognostic predictor of PX-866 for cancer treatment [54]. Here, PIK3CA is linked to cancer.